Home FOR AUTHORS Neoplasma 2007 Neoplasma Vol.54, p.181-188, 2007

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.54, p.181-188, 2007

Title: Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy
Author: B. MLADOSIEVICOVA, A. CARTER, V. KRISTOVA

Abstract: The standard anticancer therapy based on “one size fits all” modality has been determined to be ineffective or to be the cause of adverse drug reactions in many oncologic patients. Most pharmacogenetic and pharmacogenomic studies so far have been focused on toxicity of anticancer drugs such as 6- mercaptopurine, thioguanine, irinotecan, methotrexate, 5- fluorouracil (5-FU). Variation in genes are known to influence not only toxicity, but also efficacy of chemotherapeutics such as platinum analogues, 5-FU and irinotecan. The majority of current pharmacogenetic studies focus on single enzyme deficiencies as predictors of drug effects; however effects of most anticancer drugs are determined by the interplay of several gene products. These effects are polygenic in nature. This review briefly describes genetic variations that may impact efficacy and toxicity of drugs used in cancer chemotherapy.

Keywords: genetic variability, toxicity, efficacy, anticancer therapy
Year: 2007, Volume: 54, Issue: Page From: 181, Page To: 188

Price: 19.20 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.